Home › Funds › Soleus Capital Management, L.P. › UTHR

Soleus Capital Management, L.P. position in UTHR

UNITED THERAPEUTICS CORP DEL · Health Care

Soleus Capital Management, L.P. reported holding 225,587 shares of UTHR (UNITED THERAPEUTICS CORP DEL) in its Q2 2026 13F filing — a position valued at US$122.2M, representing 4.21% of its reported portfolio and ranking #6 among its reported holdings. Soleus Capital Management, L.P. has disclosed UTHR holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)225.59K sh
Reported value held$122.23M
Portfolio Weight4.21%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s UTHR position evolved

Soleus Capital Management, L.P. first disclosed a stake in UTHR in Q3 2023 at 287,165 shares (US$64.9M). The position peaked in Q2 2026 at 225,587 shares, worth US$122.2M. Across 12 filings, Soleus Capital Management, L.P. increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 225,587 shares valued at US$122.2M — an increase of 38,400 shares quarter over quarter.. Notable position changes include a 46% trim in Q2 2024 (shares rose 12% over the following quarter), a 60% trim in Q4 2025 (shares rose 22% over the following quarter), a 212% increase in Q1 2026 (shares fell 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 287.17K $64.86M New
Q4 2023 249.45K $54.85M Reduce
Q1 2024 259.75K $59.67M Add
Q2 2024 141.50K $45.07M Reduce
Q3 2024 101.89K $36.51M Reduce
Q4 2024 109.39K $38.60M Add
Q1 2025 155.39K $47.90M Add
Q2 2025 209.79K $60.28M Add
Q3 2025 150.00K $62.88M Reduce
Q4 2025 60.00K $29.23M Reduce
Q1 2026 187.19K $111.00M Add
Q2 2026 225.59K $122.23M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About UTHR and 13F data

UTHR (UNITED THERAPEUTICS CORP DEL) is a Health Care company. 43 other funds we track also report a position in UTHR — the largest reported positions include Avoro Capital Advisors LLC (US$1.51B), Renaissance Technologies (US$925.8M), ASSETMARK, INC (US$338.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding UTHR

All UTHR fund holders →

FAQ

How long has Soleus Capital Management, L.P. held UTHR?

Soleus Capital Management, L.P. has disclosed UTHR holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Soleus Capital Management, L.P.'s current position in UTHR?

As of Q2 2026, Soleus Capital Management, L.P. holds 225.59K shares of UTHR (UNITED THERAPEUTICS CORP DEL), valued at $122.23M, representing 4.21% of its reported portfolio and ranking #6.

Has Soleus Capital Management, L.P. been buying or selling UTHR?

In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. increased its position in UTHR. The position peaked in Q2 2026 at 225.59K shares.

Which other funds hold UTHR?

Other major institutional holders of UTHR include Avoro Capital Advisors LLC, Renaissance Technologies, ASSETMARK, INC, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.